StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/309% below fair value
$2.72−0.18 (-6.37%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

Recursion Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Recursion Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$350.48M. For fiscal 2025 it was -$371.81M. The highest annual figure on record is -$45.40M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$371.81M–
FY2024Dec 31, 2024-$359.17M–
FY2023Dec 31, 2023-$287.78M–
FY2022Dec 31, 2022-$83.52M–
FY2021Dec 31, 2021-$158.61M–
FY2020Dec 31, 2020-$45.40M–
FY2019Dec 31, 2019-$57.04M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$105.95M–
Q1 FY2026Mar 31, 2026-$81.10M–
Q4 FY2025Dec 31, 2025-$46.07M–
Q3 FY2025Sep 30, 2025-$117.36M–
Q2 FY2025Jun 30, 2025-$76.42M–
Q1 FY2025Mar 31, 2025-$131.96M–
Q4 FY2024Dec 31, 2024-$115.43M–
Q3 FY2024Sep 30, 2024-$59.23M–
Q2 FY2024Jun 30, 2024-$82.22M–
Q1 FY2024Mar 31, 2024-$102.30M–
Q4 FY2023Dec 31, 2023-$74.08M–
Q3 FY2023Sep 30, 2023-$72.92M–
Q2 FY2023Jun 30, 2023-$67.47M–
Q1 FY2023Mar 31, 2023-$73.32M-194.7%
Q4 FY2022Dec 31, 2022-$44.75M–
Q3 FY2022Sep 30, 2022-$54.54M–
Q2 FY2022Jun 30, 2022-$61.62M–
Q1 FY2022Mar 31, 2022$77.39M–
Q4 FY2021Dec 31, 2021-$61.16M-813.4%
Q3 FY2021Sep 30, 2021-$33.05M–
Q2 FY2021Jun 30, 2021-$33.65M–
Q1 FY2021Mar 31, 2021-$30.76M–
Q4 FY2020Dec 31, 2020$8.57M–
Q3 FY2020Sep 30, 2020-$19.46M–
Q2 FY2020Jun 30, 2020-$16.70M–
Q1 FY2020Mar 31, 2020-$17.82M–

More Recursion Pharmaceuticals figures

See a number that looks wrong?